Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1

Skye Bioscience, Inc.

Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
Dr. Jenkins receives annual cash retainer of $40,000 plus committee retainers; option for 40,000 shares vesting over 1 year.
Director Margaret Dalesandro to resign effective Aug 1, 2024, citing no disagreement with company.
Dr. Jenkins brings 25+ years pharma/biotech experience including roles at Merck Serono, BMS, and as CEO of Dimension Therapeutics.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Margaret Dalesandro

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-08-01
Filed: March 4, 2024, 6:59 PM ET

Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.

Appointed

Annalisa Jenkins

Director

SKYE · Skye Bioscience, Inc.

Effective: 2024-02-29
Filed: March 4, 2024, 6:59 PM ET

appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Margaret Dalesandro resigned as Director at Skye Bioscience, Inc..

Action: resigned
Role: Director

Exact text from the filing

Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Annalisa Jenkins was appointed as Director at Skye Bioscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-24-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.